Cargando…

Experience with Dopamine Agonists in the Treatment of Prolactinomas

The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of the patient P. The most important effects of cab...

Descripción completa

Detalles Bibliográficos
Autores principales: Barabash, Nadiya Ye., Tykhonova, Tetiana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Vilnius University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799005/
https://www.ncbi.nlm.nih.gov/pubmed/37733390
http://dx.doi.org/10.15388/Amed.2022.29.2.15
_version_ 1784861025987723264
author Barabash, Nadiya Ye.
Tykhonova, Tetiana M.
author_facet Barabash, Nadiya Ye.
Tykhonova, Tetiana M.
author_sort Barabash, Nadiya Ye.
collection PubMed
description The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of the patient P. The most important effects of cabergoline demonstrated in this clinical case are reduction in the size of the adenoma from macro to micro, reverse development of chiasmal syndrome with restoration of visual functions, achievement and maintenance of the target level of prolactin. Besides the article focused on the possible development of primary and secondary resistance to dopamine analogues. One of such difficult clinical scenarios is illustrated by the clinical case of patient M., who was treated with different dopamine analogues with the development of secondary dopamine resistance. Along with described in literature possible mechanisms for its development in our patient we also suggest the role of prolonged inadequate therapy with dopamine agonists, when the dose of the drug was not properly adjusted, despite not reaching the target prolactin level. The literature considers several ways of optimization of treatment in resistant patients but despite of this fact it remains one of unresolved problems in the management of patients with hyperprolactinemia.
format Online
Article
Text
id pubmed-9799005
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Vilnius University Press
record_format MEDLINE/PubMed
spelling pubmed-97990052023-01-03 Experience with Dopamine Agonists in the Treatment of Prolactinomas Barabash, Nadiya Ye. Tykhonova, Tetiana M. Acta Med Litu Case Studies The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of the patient P. The most important effects of cabergoline demonstrated in this clinical case are reduction in the size of the adenoma from macro to micro, reverse development of chiasmal syndrome with restoration of visual functions, achievement and maintenance of the target level of prolactin. Besides the article focused on the possible development of primary and secondary resistance to dopamine analogues. One of such difficult clinical scenarios is illustrated by the clinical case of patient M., who was treated with different dopamine analogues with the development of secondary dopamine resistance. Along with described in literature possible mechanisms for its development in our patient we also suggest the role of prolonged inadequate therapy with dopamine agonists, when the dose of the drug was not properly adjusted, despite not reaching the target prolactin level. The literature considers several ways of optimization of treatment in resistant patients but despite of this fact it remains one of unresolved problems in the management of patients with hyperprolactinemia. Vilnius University Press 2022 2022-06-29 /pmc/articles/PMC9799005/ /pubmed/37733390 http://dx.doi.org/10.15388/Amed.2022.29.2.15 Text en Copyright © 2022 Nadiya Ye. Barabash, Tetiana М. Tykhonova. Published by Vilnius University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Case Studies
Barabash, Nadiya Ye.
Tykhonova, Tetiana M.
Experience with Dopamine Agonists in the Treatment of Prolactinomas
title Experience with Dopamine Agonists in the Treatment of Prolactinomas
title_full Experience with Dopamine Agonists in the Treatment of Prolactinomas
title_fullStr Experience with Dopamine Agonists in the Treatment of Prolactinomas
title_full_unstemmed Experience with Dopamine Agonists in the Treatment of Prolactinomas
title_short Experience with Dopamine Agonists in the Treatment of Prolactinomas
title_sort experience with dopamine agonists in the treatment of prolactinomas
topic Case Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799005/
https://www.ncbi.nlm.nih.gov/pubmed/37733390
http://dx.doi.org/10.15388/Amed.2022.29.2.15
work_keys_str_mv AT barabashnadiyaye experiencewithdopamineagonistsinthetreatmentofprolactinomas
AT tykhonovatetianam experiencewithdopamineagonistsinthetreatmentofprolactinomas